Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$32.06
+1.5%
$27.46
$23.15
$127.20
$12.40B1.848.88 million shs5.97 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$56.64
+2.4%
$50.52
$32.50
$60.60
$3.51B2.26839,890 shs614,019 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.63
+0.7%
$14.84
$12.26
$16.89
$12.22B0.331.52 million shs1.03 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$15.29
+11.6%
$0.00
$0.08
$83.60
$7.56B2.2913.34 million shs1.35 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-3.92%-2.95%+18.41%+25.37%-74.00%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+0.16%+11.31%-1.86%+20.79%+50.53%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.14%-1.46%-7.87%+8.38%-9.53%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-6.68%-29.05%+1,369,999,900.00%+1,369,999,900.00%+1,369,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.4326 of 5 stars
4.01.00.04.63.22.50.6
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
1.4541 of 5 stars
2.51.00.00.03.62.50.0
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.768 of 5 stars
2.54.01.70.02.20.01.9
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.3368 of 5 stars
0.03.00.00.02.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6145.39% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$66.1016.70% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.00
Buy$16.9515.84% Upside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTGX, RDY, MRNA, and RGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
6/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00
6/5/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/5/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$14.44 ➝ $16.90
6/3/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/19/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.95N/AN/A$28.33 per share1.13
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$207.80M16.89$4.63 per share12.23$11.33 per share5.00
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B3.21$1.04 per share14.10$4.73 per share3.09
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7575.52N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.6622.1717.845.1617.38%17.98%12.24%7/25/2025 (Estimated)
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$4.30MN/A0.00N/AN/AN/AN/AN/A

Latest PTGX, RDY, MRNA, and RGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
8/5/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53N/AN/AN/A$8.32 millionN/A
7/25/2025Q1 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.19N/AN/AN/A$88.27 billionN/A
5/9/2025Q4 24/25
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.080.55%N/A12.12%N/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$0.885.76%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
17.25
17.26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.02
1.92
1.37
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.98 million58.95 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.90 million818.20 millionOptionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10494.49 millionN/AN/A

Recent News About These Companies

Best Chinese Stocks Worth Watching - July 6th
Top Chinese Stocks To Consider - July 4th
Regencell Bioscience Holdings Ltd (RGC)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$32.06 +0.48 (+1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$32.07 +0.01 (+0.04%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$56.64 +1.32 (+2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$56.62 -0.02 (-0.04%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.63 +0.10 (+0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$14.62 -0.02 (-0.12%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$15.29 +1.59 (+11.61%)
As of 04:00 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.